Lindbrook Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Lindbrook Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.64K	Sell	198 -27	-12%	-$1.02K	﹤0.01%	1836
2024 Q4	$8.82K	Sell	225 -4	-2%	-$165	﹤0.01%	1714
2024 Q3	$9.02K	Sell	229 -94	-29%	-$3.79K	﹤0.01%	1725
2024 Q2	$12.6K	Buy	323 +320	+10,667%	+$12.8K	﹤0.01%	1503
2024 Q1	$129	Buy	+3	New	+$138	﹤0.01%	2606
2023 Q4	–	Sell	-14	Closed	-$478	–	2832
2023 Q3	$478	Buy	+14	New	+$524	﹤0.01%	2548
2021 Q4	–	Sell	-1,000	Closed	-$15K	–	2220
2021 Q3	$15K	Buy	+1,000	New	+$17.4K	﹤0.01%	851
2019 Q3	–	Sell	-750	Closed	-$7K	–	1547
2019 Q2	$7K	Buy	+750	New	+$7.18K	﹤0.01%	997

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lindbrook Capital's XENE Position: Q1 2025 in Review

Lindbrook Capital reduced its Xenon Pharmaceuticals (XENE) stake by 12% in Q1 2025, selling an estimated $1.02K and leaving 198 shares worth $6.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1836.

Lindbrook Capital first reported a position in XENE in Q2 2019 and has held it in 8 quarters since. The position peaked at $15K in Q3 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

Lindbrook Capital held 198 shares of Xenon Pharmaceuticals worth $6.64K as of Q1 2025.
Lindbrook Capital sold 27 Xenon Pharmaceuticals shares in Q1 2025, an estimated $1.02K.
Xenon Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1836 holding.
Lindbrook Capital first reported a position in Xenon Pharmaceuticals in Q2 2019 and has held it in 8 quarters since.
Lindbrook Capital's Xenon Pharmaceuticals position peaked at $15K in Q3 2021.
206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.